Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis.
| Publication Type | Academic Article |
| Authors | Markowitz K, Safi N, Pliska-Bloch I, Kaunzner U, Luu H, Sisman M, Wang Y, Nguyen T, Hurtado Rúa S, Gauthier S |
| Journal | Ann Clin Transl Neurol |
| Date Published | 03/10/2026 |
| ISSN | 2328-9503 |
| Abstract | Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron-laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab-treated patients with at least one PRL on quantitative susceptibility mapping (QSM), 97 PRLs were identified. Before treatment, PRLs showed higher QSM values than non-PRLs (p = 0.001), indicating iron enrichment. After treatment, PRLs demonstrated a greater QSM reduction (p < 0.001), with an accelerated decline in susceptibility. These findings suggest ocrelizumab may attenuate iron-related inflammation in PRLs. |
| DOI | 10.1002/acn3.70357 |
| PubMed ID | 41806161 |